Ozempic Boosts Denmark's Economy

The soaring demand for Ozempic and its sister weight-loss drug Wegovy has boosted Denmark's GDP by around 1.7-2 percentage points in 2022-2023. This surge has been driven by Novo Nordisk, the Copenhagen-based pharmaceutical giant owned by Novo Holdings A/S, whose profits and share price climbed nearly 40-45%, lifting its market capitalization above the size of Denmark's entire economy and funneling billions into jobs, infrastructure, tax revenue, and domestic investments.

Previous Fact Next Fact